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Abstract 
Purpose: To investigate the expression levels of matrix metalloproteinases and their inhibitors in 
ulcerative colitis patients 
Methods: In this investigation, the expression of matrix metalloproteinases (MMPs) and tissue inhibitors 
of metalloproteinases (TIMPs) were evaluated in 50 patients with ulcerative colitis, which comprised of 
36 males and 14 females. The tissue samples were obtained from the core needle of sample and 
evaluated using immunochemistry techniques. 
Results: The prevailing MMP-9 and TIMP-1 expressions in the glandular epithelium and inflammatory 
cells were observed. In addition, the expressions were coupled with architectural changes in the tissues 
and inflammation in the lamina propria. It was also observed that the expression of MMPs and inhibitors 
with weak activation established the progress of ulcerative colitis. Statistical correlation between the 
MMP expressions and histopathological parameters was also very significant. MMP expression 
correlated with weaker expression of TIMPs. 
Conclusion: MMPs, especially MMP-2, MMP-7 and MMP-9, may provide a potential target for 
controlling ulcerative colitis.  
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Ulcerative colitis (UC) is a chronic form of 
inflammatory bowel disease (IBD) [1]. It usually 
remits inflammation in the large intestine [1]. It is 
also considered as an autoimmune disease 
influenced by environmental factors and genetic 
factors [2]. UC causes ulcer and inflammation in 
the colon in the large intestine. UC is a long 
lasting disease which starts in early adulthood 
and may last throughout life and existence of the 
disease is difficult to confirm until intestinal 
confirmation [3]. Moreover the incidence of 
ulcerative colitis has gradually increased in 
recent years with a higher rate of incidence in 
developed countries [4].  
 
The symptoms of UC include diarrhea with blood, 
fever, abdominal pain and weight loss [5]. The 
cause of the disease is not properly understood, 
which is presumed a genetic risk. There are also 
certain reports which indicate the higher rate of 
UC is due to western lifestyle and diet [6]. The 
treatment of the disease includes the prescription 
of anti-inflammatory drugs and certain therapy, 
which targets the immune response specific 
mechanisms [7]. In severe cases of UC there is a 
need for the surgical removal of the large 
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intestine partially or total which is called 
colectomy [8].  
 
Matrix metalloproteinases (MMPs) belong to a 
group of proteolytic calcium-dependent enzyme 
which contains zinc, categorized under the 
metzincin superfamily [9,10]. These enzymes 
play an important role in the extracellular matrix 
protein degradation by cleaving its components 
such as cell surface receptors. In addition, these 
proteins are involved in processing certain 
bioactive molecules [11]. MMPs are also involved 
in proliferation of cell; cell adhesion and 
dispersion, programed cell death and cell 
differentiation [12]. MMPs are also regulated by 
cytokines and certain growth factors and 
hormones. They are also excreted by endothelial 
cells, neutrophils, macrophages, neutrophils and 
lymphocytes [13]. Four distinct domains 
comprise the three dimensional structure of 
MMPs – the catalytic domain, the pro-peptide 
domain, hinge region and   haemopexin-like 
domain which is on the C-terminal [9,14].  
 
MMPs are known to have a common domain 
structure. These domains are the pro-peptide, 
the catalytic domain, and the haemopexin-like C-
terminal domain, that is associated with the 
catalytic domain by a flexible hinge region. There 
are 26 types of MMPs which is categorized under 
six different sub groups [9]. MMPs are mostly 
controlled and inhibited by the tissue inhibitors of 
metalloproteinases (TIMPs) which comprise of 
TIMP-1, TIMP-2, TIMP-3, and TIMP-4 [15]. 
TIMPs usually have two domains that are 
functionally distinctive. For maintaining and 
remodeling of the cells and tissue functions there 
is a need for controlling the balance of MMPs 
and TIMPs. The imbalance of these proteins 
leads to disease such as tissue fibrosis, 
cardiovascular diseases and ulcers and tissue 
inflammations [15].  
 
Thus, the present investigation aims on the 
evaluation of the immune-histochemical 
association with the Matrix Matalloprotienase 
(MMP-2, MMP-7 and MMP-9) and Tissue 
Inhibitors of Metalloproteinases (TIMP-1 and 
TIMP-2) in 50 cases of patients with ulcerative 
colitis and their correlation with histochemical 
and pathological parameters. The investigation 
will aid in understanding the expression of these 
proteins in ulcerative colitis which may provide a 




The study was performed in compliance with the 
National Institutes of Health guidelines and was 
approved by the Local Bioethics Committee of 
The First Affiliated Hospital of Nanchang 
University, Nanchang, Jiangxi, China. The 
present investigation consists of fifty patients (N 
= 50) with 36 males and 14 females diagnosed 
with UC. All the patients were over 21 years of 
age.  The biopsy samples were obtained from 
the core needle of sample which was further 
embedded with blocks of paraffin obtained from 
the Department of Gastroenterology and 
Surgery, Chinese Central Hospital, People RC. 
 
All the reagents such as rabbit anti-Smad4, 
rabbit anti-Smad6, and rabbit anti-Smad7 
monoclonal antibody of matrix metalloproteinase 
and mouse monoclonal antibody tissue inhibitor 
of matrix metalloproteinase 1 and 2 were 
purchased from Novocastra Reagents, Leica 
Microsystems, Germany. All the sections used in 
the present investigation were counter stained 
with hematoxylin and eosin (H&E) with regular 
histopathological evaluation. 
 
The tissue slides which were fixed with formalin 
and embedded in paraffin were cut using a HM 
450 Sliding Microtome (Thermo Fisher Scientific, 
USA) with a thicker section of 4 µm. The sections 
were deparaffinized in xylene and rehydrated 
with alcohol. The sections of MMP-2 and TIMP-1 
were further placed in a microwave oven for 30 
min and treated with citrate buffer, then 
subjected to retrieval of the antigen using a 
pressure chamber. The slides were incubated 
with their corresponding primary antibodies for 
MMP-2, MMP-7, MMP-9, TIMP-1 and TIMP-2 
respectively diluted to 1:70 and kept overnight at 
4 oC. The incubation continued for 20-30 min in 
their amplifying reagent at room temperature. 
The resulting antigen-antibody complex activity 
was detected and visualized using 
diaminobenzidine (DAB) and it was further 
counterstained with hematoxylin. The data 
analysis and correlation analysis for statistical 
significance was carried out using SPSS 18 
statistical software. The p-value less than 0.05 




A total of 50 patients were analyzed in the 
present investigation of the patients with 
ulcerative colitis. Four cases of acute epithelial 
dysplasia were noticed, with 14 moderate cases 
and 20 indefinite cases. Twelve patients were 
noticed with negative or no grade of epithelial 
dysplasia (Table 1). In addition, the disease 
activity of ulcerative colitis was evaluated based 
on the protocol developed by Geboes et al [16] 
which indicated 30 subjects having chronic cases 
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of UC, 8 active cases and 12 subjects with 
inactive UC (Table 1). 
 
The expression analysis on glandular cells 
showed that, the expression of MMP-2 was weak 
in glandular epithelium in 60 cases covering 73.3 
% of the patients having UC and in inflammatory 
cells covering 72 % of the cases. The expression 
of MMP-2 was average and strong in the 
glandular tubes covering 16 and 8 % of the case 
respectively, compared to 10 and 2 % in the case 
of inflammatory cells respectively (Table 2). 
 
On the contrary, the expression of MMP-7 
protein was absent in 29 patients covering 58 % 
of the cases in the glandular epithelium as 
opposed to the 6 % of the cases in inflammatory 
cells. Also, 22 % of the case has a weak 
expression of glandular cells compared to 36 % 
of the inflammatory cells. 16.1 % average 
expression and 32 % of the cases have weak 
expression of MMP-9 in both the glandular cells 
and inflammatory cells. (Fig 1) (Table 2). 
 
Furthermore, a strong expression of TIMP-1 was 
found in 32 cases covering 64 % in the glandular 
epithelium. There were 40 % of strong cases in 
cells of inflammatory infiltrates. While the 
reaction of TIMP-2 was higher in weak cases (44 
%) of glandular epithelium than in infiltration of 
inflammatory cells (33 %) (Fig 2). 
 
 
Table 1: Statistics of sex ratio, grade of dysplasia and disease activity  
 
Sex (N) Grade of dysplasia (N) Disease activity (N) 
Female Male Nil Indefinite Moderate Acute Inactive Active Chronic 
14 36 12 20 14 4 12 8 30 
N = number 
 




Ulcerative colitis (UC) 
Glandular cells (% of cases) Inflammatory cells (% of cases) 
Absent Weak Mean Strong Absent Weak Mean Strong 
MMP-2 2 (4%) 36 (72%) 8 (16%) 4 (8%) 8 (16%) 36(72%) 5(10%) 1(2%) 
MMP-7 29 (58%) 11(22%) 9 (9) 1(2%) 3(6%) 18(36%) 16(32%) 13(26%) 
MMP-9 4 (8%) 16 (32%) 11 (22%) 19 (38%) 2(4%) 16(32%) 13(26%) 19(38%) 
 
 
Figure 1: Immunohistochemical expression of MMP-2, MMP-7 and MMP-9 in glandular epithelium and 
inflammatory cells 
 





Ulcerative colitis (UC) 
Glandular cells (% of cases) Inflammatory cells (% of cases) 
Absent  Weak Mean Strong Absent Weak Mean Strong 
TIMP-1 9 (18%) 7 (14%) 2 (4%) 32 (64%) 11 (22%) 16 (32%) 3 (6%) 20 (40%) 
TIMP-2 4(8%) 22(44%) 15(30%) 9 (18%) 20 (42%) 16 (33%) 4 (8%) 8 (17%) 
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Figure 2: Immunohistochemical expression of TIMP-1 and TIMP-2 in glandular epithelium and inflammatory cells 
 
The present investigation revealed a strong 
correlation with the expression of the MMPs in 
the glandular epithelium along with the presence 
of ulcers (p = 0.051, R = 0.392). In addition, an 
increased trend was observed in the glandular 
epithelium of MMP-2 with a change in the 
architectural structure of the tissue (p = 0.076, R 
= 0.381). The presence of neutrophils in the 
lamina propria is also observed (p = 0.077, R = 
0.371). (Fig 1a) 
 
Considering MMP-7 expression in the glandular 
epithelium, most of the cases correlate with 
erosions (p = 0.031, R = 0.492). There was also 
a decrease in MMP-9 expression observed in the 
architectural tissue alterations (p = 0.067, R = − 
0.392) (Fig 1bc). The expression of MMP-2 in the 
propria of inflammatory infiltration correlated with 
the presence of neutrophils. In addition, the 
expression level of TIMP-1 corresponds with 
eosinophil in the lamina propria (p= 0.024, R = 
0.612) and neutrophils in glandular epithelium (p 
= 0.032, R = 0.0581).  In addition, a significant 
correlation was observed in the expression of 
TIMP-2 in the glandular epithelium. However, no 
significant relationship was observed the case of 





In the present investigation, the expression of 
various metaloproteinase levels with their 
inhibitors was observed in various cases based 
on the stage and advancement. The study has 
shown that the expression on MMP-7 was weak 
in glandular epithelium in 60 % of the cases 
which corresponds to inflammatory infiltration. 
The study also evidenced various destructive 
processes in the expression. However, some 
regenerative process was also observed in 
certain cases. The investigation also showed a 
weak expression of MMP-2 expression in the 
inflammatory infiltration contrasting a strong 
expression in the patients with glandular 
epithelium which has also been confirmed by von 
Lampe et al [17]. The study also noticed that 
MMP-2 expression is associated with erosions in 
the glandular epithelium. The expression of 
MMP-2 is also mainly associated with 
mesenchymal cells and neutrophils in the 
glandular epithelium and inflammatory infiltration. 
The investigation also observed an affirmative 
expression of MMP-9 both in glandular 
epithelium and inflammatory infiltration in which 
similar occurrence has been observed earlier in 
patients with ulcerative colitis [18]. Moreover, the 
protein activity was increased in ulcerative colitis 
by the homogeneity of the inflamed mucosa. 
 
The statistical analysis in the present 
investigation showed that tissue architecture of 
the colon caused changes with increasing MMP-
9 expression. These observations provide an 
impetus for MMP-9 expression on the chronic 
inflammation of the tissue lining of the colons and 
remodeling of the tissue architecture. The 
present investigation also revealed that MMP-9 
plays a crucial role in ulcerative colitis. In 
addition, there are various reports which support 
the pathogenesis of MMP-9 expression in colitis 
[19-20]. These findings may serve as a potential 
target for anti-inflammatory treatment. The 
expression of TIMP-1 and TIMP-2 also revealed 
that these proteins play a vital role in regulating 
the activity of the metalloproteinases thereby 
maintaining an equilibrium. In addition positive 
expression of TIMP-1 with an inflamed ulcer in 
ulcerative colitis has been reported earlier [21]. 
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The expression of MMPs with the inhibitors that 
have weak activation establishes the progress of 
ulcerative colitis. Furthermore, the statistical 
correlation between MMPs expression with 
histopathological parameters is very significant. 
Thus, it may be deduced that MMPs, viz, MMP-2, 
MMP-7 and MMP-9 are potential targets for 
inhibitors such as TIMP-1 and TIMP-2 to reduce 
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